JP2004533454A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004533454A5 JP2004533454A5 JP2002589483A JP2002589483A JP2004533454A5 JP 2004533454 A5 JP2004533454 A5 JP 2004533454A5 JP 2002589483 A JP2002589483 A JP 2002589483A JP 2002589483 A JP2002589483 A JP 2002589483A JP 2004533454 A5 JP2004533454 A5 JP 2004533454A5
- Authority
- JP
- Japan
- Prior art keywords
- lower alkyl
- amino
- phenyl
- pyrrolo
- benzyloxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 234
- 150000001875 compounds Chemical class 0.000 claims 71
- 125000000623 heterocyclic group Chemical group 0.000 claims 38
- -1 di-substituted amino Chemical group 0.000 claims 36
- 229910052757 nitrogen Inorganic materials 0.000 claims 24
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 22
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 21
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 20
- 229910052760 oxygen Inorganic materials 0.000 claims 20
- 239000001301 oxygen Substances 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 19
- 125000003545 alkoxy group Chemical group 0.000 claims 17
- 229910052736 halogen Inorganic materials 0.000 claims 17
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 16
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 16
- 150000002367 halogens Chemical class 0.000 claims 14
- 125000003282 alkyl amino group Chemical group 0.000 claims 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 10
- 239000011593 sulfur Chemical group 0.000 claims 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 9
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 7
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 4
- 125000006501 nitrophenyl group Chemical group 0.000 claims 4
- 125000005236 alkanoylamino group Chemical group 0.000 claims 3
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 3
- 150000001408 amides Chemical class 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- MINLECAKOASWQA-UHFFFAOYSA-N 7-[3-(aminomethyl)cyclobutyl]-5-(3-phenylmethoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(CN)CC1N1C2=NC=NC(N)=C2C(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=C1 MINLECAKOASWQA-UHFFFAOYSA-N 0.000 claims 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 125000001589 carboacyl group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 229950001413 metamfepramone Drugs 0.000 claims 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 239000007858 starting material Substances 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- CZAXYMOAFIXZDY-UHFFFAOYSA-N 1-[[3-[4-amino-5-(3-phenylmethoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]cyclobutyl]methyl]-3-propan-2-ylurea Chemical compound C1C(CNC(=O)NC(C)C)CC1N1C2=NC=NC(N)=C2C(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=C1 CZAXYMOAFIXZDY-UHFFFAOYSA-N 0.000 claims 1
- GQGMUKOYILWOIQ-UHFFFAOYSA-N 6-methyl-5-(3-phenylmethoxyphenyl)-7-[3-(pyrrolidin-1-ylmethyl)cyclobutyl]pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C12=C(N)N=CN=C2N(C2CC(CN3CCCC3)C2)C(C)=C1C(C=1)=CC=CC=1OCC1=CC=CC=C1 GQGMUKOYILWOIQ-UHFFFAOYSA-N 0.000 claims 1
- AECDBHGVIIRMOI-UHFFFAOYSA-N 7-[3-(azetidin-1-ylmethyl)cyclobutyl]-5-(3-phenylmethoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C2CC(CN3CCC3)C2)C=C1C(C=1)=CC=CC=1OCC1=CC=CC=C1 AECDBHGVIIRMOI-UHFFFAOYSA-N 0.000 claims 1
- ICHGNLVHYDFSAR-RZFKFIIISA-N C12=C(N)N=CN=C2N([C@@H]2C[C@@H](CNC3CCOCC3)C2)C(C)=C1C(C=1)=CC=CC=1OCC1=CC=CC=C1 Chemical compound C12=C(N)N=CN=C2N([C@@H]2C[C@@H](CNC3CCOCC3)C2)C(C)=C1C(C=1)=CC=CC=1OCC1=CC=CC=C1 ICHGNLVHYDFSAR-RZFKFIIISA-N 0.000 claims 1
- XQMSYQDZIAGQPB-MXVIHJGJSA-N C12=C(N)N=CN=C2N([C@@H]2C[C@H](C2)C(=O)OC)C(CC)=C1C(C=1)=CC=CC=1OCC1=CC=CC=C1 Chemical compound C12=C(N)N=CN=C2N([C@@H]2C[C@H](C2)C(=O)OC)C(CC)=C1C(C=1)=CC=CC=1OCC1=CC=CC=C1 XQMSYQDZIAGQPB-MXVIHJGJSA-N 0.000 claims 1
- AECDBHGVIIRMOI-AQYVVDRMSA-N C1=2C(N)=NC=NC=2N([C@@H]2C[C@@H](CN3CCC3)C2)C=C1C(C=1)=CC=CC=1OCC1=CC=CC=C1 Chemical compound C1=2C(N)=NC=NC=2N([C@@H]2C[C@@H](CN3CCC3)C2)C=C1C(C=1)=CC=CC=1OCC1=CC=CC=C1 AECDBHGVIIRMOI-AQYVVDRMSA-N 0.000 claims 1
- IONLBUKCCPUJIH-HCGLCNNCSA-N C1=2C(N)=NC=NC=2N([C@@H]2C[C@@H](CN3CCCCC3)C2)C=C1C(C=1)=CC=CC=1OCC1=CC=CC=C1 Chemical compound C1=2C(N)=NC=NC=2N([C@@H]2C[C@@H](CN3CCCCC3)C2)C=C1C(C=1)=CC=CC=1OCC1=CC=CC=C1 IONLBUKCCPUJIH-HCGLCNNCSA-N 0.000 claims 1
- IPUIQYUWBBQMLR-DUYHBEBVSA-N C1=2C(N)=NC=NC=2N([C@@H]2C[C@@H](CN3CCN(CC3)C=3N=CC=CC=3)C2)C=C1C(C=1)=CC=CC=1OCC1=CC=CC=C1 Chemical compound C1=2C(N)=NC=NC=2N([C@@H]2C[C@@H](CN3CCN(CC3)C=3N=CC=CC=3)C2)C=C1C(C=1)=CC=CC=1OCC1=CC=CC=C1 IPUIQYUWBBQMLR-DUYHBEBVSA-N 0.000 claims 1
- KUUHULDUODEQHB-AFARHQOCSA-N C1=2C(N)=NC=NC=2N([C@@H]2C[C@@H](CN3CCOCC3)C2)C=C1C(C=1)=CC=CC=1OCC1=CC=CC=C1 Chemical compound C1=2C(N)=NC=NC=2N([C@@H]2C[C@@H](CN3CCOCC3)C2)C=C1C(C=1)=CC=CC=1OCC1=CC=CC=C1 KUUHULDUODEQHB-AFARHQOCSA-N 0.000 claims 1
- ZXYAKTRUTLRFEX-YFJLJUBXSA-N C1C(C)OC(C)CN1C[C@@H]1C[C@@H](N2C3=NC=NC(N)=C3C(C=3C=C(OCC=4C=CC=CC=4)C=CC=3)=C2)C1 Chemical compound C1C(C)OC(C)CN1C[C@@H]1C[C@@H](N2C3=NC=NC(N)=C3C(C=3C=C(OCC=4C=CC=CC=4)C=CC=3)=C2)C1 ZXYAKTRUTLRFEX-YFJLJUBXSA-N 0.000 claims 1
- REXRZICSDNALRF-HCGLCNNCSA-N C1CN(C)CCN1C[C@@H]1C[C@@H](N2C3=NC=NC(N)=C3C(C=3C=C(OCC=4C=CC=CC=4)C=CC=3)=C2)C1 Chemical compound C1CN(C)CCN1C[C@@H]1C[C@@H](N2C3=NC=NC(N)=C3C(C=3C=C(OCC=4C=CC=CC=4)C=CC=3)=C2)C1 REXRZICSDNALRF-HCGLCNNCSA-N 0.000 claims 1
- LDRXGQRNDOVOLA-MXVIHJGJSA-N C1[C@@H](C(=O)N(C)C)C[C@@H]1N1C2=NC=NC(N)=C2C(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=C1 Chemical compound C1[C@@H](C(=O)N(C)C)C[C@@H]1N1C2=NC=NC(N)=C2C(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=C1 LDRXGQRNDOVOLA-MXVIHJGJSA-N 0.000 claims 1
- FITJQXRHQKAHRQ-WGSAOQKQSA-N C1[C@@H](C(=O)NC)C[C@@H]1N1C2=NC=NC(N)=C2C(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=C1 Chemical compound C1[C@@H](C(=O)NC)C[C@@H]1N1C2=NC=NC(N)=C2C(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=C1 FITJQXRHQKAHRQ-WGSAOQKQSA-N 0.000 claims 1
- NTMLQBGOQOGFFT-IYARVYRRSA-N C1[C@@H](C(=O)OC)C[C@@H]1N1C2=NC=NC(N)=C2C(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=C1Br Chemical compound C1[C@@H](C(=O)OC)C[C@@H]1N1C2=NC=NC(N)=C2C(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=C1Br NTMLQBGOQOGFFT-IYARVYRRSA-N 0.000 claims 1
- MGADSANUGJPJTF-MXVIHJGJSA-N C1[C@@H](C(=O)OC)C[C@@H]1N1C2=NC=NC(N)=C2C(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=C1C Chemical compound C1[C@@H](C(=O)OC)C[C@@H]1N1C2=NC=NC(N)=C2C(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=C1C MGADSANUGJPJTF-MXVIHJGJSA-N 0.000 claims 1
- MINLECAKOASWQA-UAPYVXQJSA-N C1[C@@H](CN)C[C@@H]1N1C2=NC=NC(N)=C2C(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=C1 Chemical compound C1[C@@H](CN)C[C@@H]1N1C2=NC=NC(N)=C2C(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=C1 MINLECAKOASWQA-UAPYVXQJSA-N 0.000 claims 1
- WBYYXJHMBIEJCC-AFARHQOCSA-N C1[C@@H](CNC(=O)N(CC)CC)C[C@@H]1N1C2=NC=NC(N)=C2C(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=C1 Chemical compound C1[C@@H](CNC(=O)N(CC)CC)C[C@@H]1N1C2=NC=NC(N)=C2C(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=C1 WBYYXJHMBIEJCC-AFARHQOCSA-N 0.000 claims 1
- CQQQRDIANWGYBY-KESTWPANSA-N C1[C@@H](CNC)C[C@@H]1N1C2=NC=NC(N)=C2C(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=C1 Chemical compound C1[C@@H](CNC)C[C@@H]1N1C2=NC=NC(N)=C2C(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=C1 CQQQRDIANWGYBY-KESTWPANSA-N 0.000 claims 1
- XRMMWXGVGDPTGL-AQYVVDRMSA-N CC(C)(C)NC(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 Chemical compound CC(C)(C)NC(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 XRMMWXGVGDPTGL-AQYVVDRMSA-N 0.000 claims 1
- JSOCIINBZIRFJJ-AQYVVDRMSA-N CC(C)C(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 Chemical compound CC(C)C(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 JSOCIINBZIRFJJ-AQYVVDRMSA-N 0.000 claims 1
- UNUAWXMVQLZJRI-AQYVVDRMSA-N CC(C)S(=O)(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 Chemical compound CC(C)S(=O)(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 UNUAWXMVQLZJRI-AQYVVDRMSA-N 0.000 claims 1
- CZOJVEPPEOWDQJ-YFJLJUBXSA-N CC1CCC(C)N1C[C@@H]1C[C@@H](N2C3=NC=NC(N)=C3C(C=3C=C(OCC=4C=CC=CC=4)C=CC=3)=C2)C1 Chemical compound CC1CCC(C)N1C[C@@H]1C[C@@H](N2C3=NC=NC(N)=C3C(C=3C=C(OCC=4C=CC=CC=4)C=CC=3)=C2)C1 CZOJVEPPEOWDQJ-YFJLJUBXSA-N 0.000 claims 1
- VCEIHCLYWKZRCQ-AFARHQOCSA-N CCCCNC(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 Chemical compound CCCCNC(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 VCEIHCLYWKZRCQ-AFARHQOCSA-N 0.000 claims 1
- LDTLIYZCJAHYBU-AQYVVDRMSA-N CCCNC(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 Chemical compound CCCNC(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 LDTLIYZCJAHYBU-AQYVVDRMSA-N 0.000 claims 1
- CWHGEXXQNLPSHD-ALOJWSFFSA-N CCN(CC)CCOC(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 Chemical compound CCN(CC)CCOC(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 CWHGEXXQNLPSHD-ALOJWSFFSA-N 0.000 claims 1
- IHDHVOBYVYYNDS-XUTJKUGGSA-N CCNC(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 Chemical compound CCNC(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 IHDHVOBYVYYNDS-XUTJKUGGSA-N 0.000 claims 1
- COONFDJMHJHRBM-ALOJWSFFSA-N CCOC(=O)N1CCN(C[C@H]2C[C@@H](C2)n2cc(-c3cccc(OCc4ccccc4)c3)c3c(N)ncnc23)CC1 Chemical compound CCOC(=O)N1CCN(C[C@H]2C[C@@H](C2)n2cc(-c3cccc(OCc4ccccc4)c3)c3c(N)ncnc23)CC1 COONFDJMHJHRBM-ALOJWSFFSA-N 0.000 claims 1
- PYYNBGZIQCNCCI-XUTJKUGGSA-N CCOC(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 Chemical compound CCOC(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 PYYNBGZIQCNCCI-XUTJKUGGSA-N 0.000 claims 1
- VFKIZJLNGDYBKT-AQYVVDRMSA-N CCOCC(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 Chemical compound CCOCC(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 VFKIZJLNGDYBKT-AQYVVDRMSA-N 0.000 claims 1
- OWXINVKOOZWOEN-XUTJKUGGSA-N CCS(=O)(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 Chemical compound CCS(=O)(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 OWXINVKOOZWOEN-XUTJKUGGSA-N 0.000 claims 1
- WNLYZRUMUOYMRP-KESTWPANSA-N CCc1c(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc2n1[C@H]1C[C@H](CO)C1 Chemical compound CCc1c(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc2n1[C@H]1C[C@H](CO)C1 WNLYZRUMUOYMRP-KESTWPANSA-N 0.000 claims 1
- HFMCZQFICHRAFM-XUTJKUGGSA-N CN(C)C(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 Chemical compound CN(C)C(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 HFMCZQFICHRAFM-XUTJKUGGSA-N 0.000 claims 1
- HODGCSQBGRCWLO-HCGLCNNCSA-N CN(C)CCCNC(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 Chemical compound CN(C)CCCNC(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 HODGCSQBGRCWLO-HCGLCNNCSA-N 0.000 claims 1
- JTAVVFISQTXCHE-AFARHQOCSA-N CN(C)CCNC(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 Chemical compound CN(C)CCNC(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 JTAVVFISQTXCHE-AFARHQOCSA-N 0.000 claims 1
- USHBLDDYCVMTBO-AFARHQOCSA-N CN(C)CCOC(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 Chemical compound CN(C)CCOC(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 USHBLDDYCVMTBO-AFARHQOCSA-N 0.000 claims 1
- MQBSLITVUSARHC-XUTJKUGGSA-N CN(C)C[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 Chemical compound CN(C)C[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 MQBSLITVUSARHC-XUTJKUGGSA-N 0.000 claims 1
- HIPDDNUTKGLJGM-ALOJWSFFSA-N CN1CCN(CC(=O)NC[C@H]2C[C@@H](C2)n2cc(-c3cccc(OCc4ccccc4)c3)c3c(N)ncnc23)CC1 Chemical compound CN1CCN(CC(=O)NC[C@H]2C[C@@H](C2)n2cc(-c3cccc(OCc4ccccc4)c3)c3c(N)ncnc23)CC1 HIPDDNUTKGLJGM-ALOJWSFFSA-N 0.000 claims 1
- MEDPKRVFVDCJBF-YOCNBXQISA-N CN1CCN(CCOC(=O)NC[C@H]2C[C@@H](C2)n2cc(-c3cccc(OCc4ccccc4)c3)c3c(N)ncnc23)CC1 Chemical compound CN1CCN(CCOC(=O)NC[C@H]2C[C@@H](C2)n2cc(-c3cccc(OCc4ccccc4)c3)c3c(N)ncnc23)CC1 MEDPKRVFVDCJBF-YOCNBXQISA-N 0.000 claims 1
- OOFFWNVNYZXYNM-ALOJWSFFSA-N CN1CCN(C[C@H]2C[C@@H](C2)n2c(C)c(-c3cccc(OCc4ccccc4)c3)c3c(N)ncnc23)CC1 Chemical compound CN1CCN(C[C@H]2C[C@@H](C2)n2c(C)c(-c3cccc(OCc4ccccc4)c3)c3c(N)ncnc23)CC1 OOFFWNVNYZXYNM-ALOJWSFFSA-N 0.000 claims 1
- OQIGTHHTVJUMHD-KESTWPANSA-N CNC(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 Chemical compound CNC(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 OQIGTHHTVJUMHD-KESTWPANSA-N 0.000 claims 1
- FEBYEMVQPQEWMY-KESTWPANSA-N COC(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 Chemical compound COC(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 FEBYEMVQPQEWMY-KESTWPANSA-N 0.000 claims 1
- BEULOCGXDTYSCT-AQYVVDRMSA-N COCCOC(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 Chemical compound COCCOC(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 BEULOCGXDTYSCT-AQYVVDRMSA-N 0.000 claims 1
- MGHHKOHAEAPKFP-AFARHQOCSA-N COCCOCC(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 Chemical compound COCCOCC(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 MGHHKOHAEAPKFP-AFARHQOCSA-N 0.000 claims 1
- UNFLVZMMYVSVKS-HCGLCNNCSA-N COc1ccc(cc1)S(=O)(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 Chemical compound COc1ccc(cc1)S(=O)(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 UNFLVZMMYVSVKS-HCGLCNNCSA-N 0.000 claims 1
- NCLPAIVFVXOXAA-KESTWPANSA-N CS(=O)(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 Chemical compound CS(=O)(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 NCLPAIVFVXOXAA-KESTWPANSA-N 0.000 claims 1
- FOANWBYUHRTOOL-AFARHQOCSA-N Cc1c(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc2n1[C@H]1C[C@H](CN2CCC2)C1 Chemical compound Cc1c(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc2n1[C@H]1C[C@H](CN2CCC2)C1 FOANWBYUHRTOOL-AFARHQOCSA-N 0.000 claims 1
- DJLBNZPUIHXQFP-QLBJFCOMSA-N Cc1c(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc2n1[C@H]1C[C@H](CN2CCC[C@@H]2CO)C1 Chemical compound Cc1c(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc2n1[C@H]1C[C@H](CN2CCC[C@@H]2CO)C1 DJLBNZPUIHXQFP-QLBJFCOMSA-N 0.000 claims 1
- HRYFOWNOBBOWFG-KESTWPANSA-N Cc1c(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc2n1[C@H]1C[C@H](CO)C1 Chemical compound Cc1c(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc2n1[C@H]1C[C@H](CO)C1 HRYFOWNOBBOWFG-KESTWPANSA-N 0.000 claims 1
- JMLNWLNOJJFSMV-ALOJWSFFSA-N Cc1ccc(cc1)S(=O)(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 Chemical compound Cc1ccc(cc1)S(=O)(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 JMLNWLNOJJFSMV-ALOJWSFFSA-N 0.000 claims 1
- OBOLLMDLQKRYKB-DUYHBEBVSA-N Cc1cccc(CNC(=O)NC[C@H]2C[C@@H](C2)n2cc(-c3cccc(OCc4ccccc4)c3)c3c(N)ncnc23)c1 Chemical compound Cc1cccc(CNC(=O)NC[C@H]2C[C@@H](C2)n2cc(-c3cccc(OCc4ccccc4)c3)c3c(N)ncnc23)c1 OBOLLMDLQKRYKB-DUYHBEBVSA-N 0.000 claims 1
- 239000007818 Grignard reagent Substances 0.000 claims 1
- ZNQWHKOHXUWMLD-UAPYVXQJSA-N NC(=N)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 Chemical compound NC(=N)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 ZNQWHKOHXUWMLD-UAPYVXQJSA-N 0.000 claims 1
- BZMLRFHDZLWAEN-UCWUDVSLSA-N NC(=O)C1CCCN(C[C@H]2C[C@@H](C2)n2cc(-c3cccc(OCc4ccccc4)c3)c3c(N)ncnc23)C1 Chemical compound NC(=O)C1CCCN(C[C@H]2C[C@@H](C2)n2cc(-c3cccc(OCc4ccccc4)c3)c3c(N)ncnc23)C1 BZMLRFHDZLWAEN-UCWUDVSLSA-N 0.000 claims 1
- PNEPNZDINPZUFR-UAPYVXQJSA-N NC(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 Chemical compound NC(=O)NC[C@H]1C[C@@H](C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 PNEPNZDINPZUFR-UAPYVXQJSA-N 0.000 claims 1
- FONYISGQUQXHMY-UAPYVXQJSA-N NC=1C2=C(N=CN1)N(C=C2C2=CC(=CC=C2)OCC2=CC=CC=C2)[C@@H]2C[C@H](C2)CNC(O)=O Chemical compound NC=1C2=C(N=CN1)N(C=C2C2=CC(=CC=C2)OCC2=CC=CC=C2)[C@@H]2C[C@H](C2)CNC(O)=O FONYISGQUQXHMY-UAPYVXQJSA-N 0.000 claims 1
- AMEJSINMHMEDLL-AFARHQOCSA-N Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCC(O)CC2)C1 Chemical compound Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCC(O)CC2)C1 AMEJSINMHMEDLL-AFARHQOCSA-N 0.000 claims 1
- VHKIWYHFKMOBQJ-ALOJWSFFSA-N Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCCCC2)C1 Chemical compound Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCCCC2)C1 VHKIWYHFKMOBQJ-ALOJWSFFSA-N 0.000 claims 1
- FVDWCEYQBCTACG-AFARHQOCSA-N Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCSCC2)C1 Chemical compound Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCSCC2)C1 FVDWCEYQBCTACG-AFARHQOCSA-N 0.000 claims 1
- JUFWVKHHKZAVCR-ALOJWSFFSA-N Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CNC(=O)CN2CCCCC2)C1 Chemical compound Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CNC(=O)CN2CCCCC2)C1 JUFWVKHHKZAVCR-ALOJWSFFSA-N 0.000 claims 1
- GVSBCSHBBJBDIZ-AFARHQOCSA-N Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CNC(=O)N2CCCC2)C1 Chemical compound Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CNC(=O)N2CCCC2)C1 GVSBCSHBBJBDIZ-AFARHQOCSA-N 0.000 claims 1
- KIWNKRSGKFTXPP-HCGLCNNCSA-N Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CNC(=O)N2CCCCC2)C1 Chemical compound Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CNC(=O)N2CCCCC2)C1 KIWNKRSGKFTXPP-HCGLCNNCSA-N 0.000 claims 1
- RLCZUYQBURMNDZ-AFARHQOCSA-N Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CNC(=O)N2CCOCC2)C1 Chemical compound Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CNC(=O)N2CCOCC2)C1 RLCZUYQBURMNDZ-AFARHQOCSA-N 0.000 claims 1
- LPQONMCVBNYRRX-YOCNBXQISA-N Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CNC(=O)NCCCN2CCOCC2)C1 Chemical compound Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CNC(=O)NCCCN2CCOCC2)C1 LPQONMCVBNYRRX-YOCNBXQISA-N 0.000 claims 1
- KDJUOUXKVYJHEQ-ALOJWSFFSA-N Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CNC(=O)NCCN2CCOCC2)C1 Chemical compound Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CNC(=O)NCCN2CCOCC2)C1 KDJUOUXKVYJHEQ-ALOJWSFFSA-N 0.000 claims 1
- HTRBGRLCGGGPPN-YOCNBXQISA-N Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CNC(=O)NCc2ccccc2)C1 Chemical compound Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CNC(=O)NCc2ccccc2)C1 HTRBGRLCGGGPPN-YOCNBXQISA-N 0.000 claims 1
- UZEIODJMSHKOGA-NDZWVUITSA-N Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CNC23CC4CC(CC(C4)C2)C3)C1 Chemical compound Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CNC23CC4CC(CC(C4)C2)C3)C1 UZEIODJMSHKOGA-NDZWVUITSA-N 0.000 claims 1
- MWCCQHZMZNIJFZ-SAIGFBBZSA-N Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CNS(=O)(=O)c2ccc(cc2)[N+]([O-])=O)C1 Chemical compound Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CNS(=O)(=O)c2ccc(cc2)[N+]([O-])=O)C1 MWCCQHZMZNIJFZ-SAIGFBBZSA-N 0.000 claims 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 1
- 125000005036 alkoxyphenyl group Chemical group 0.000 claims 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- LSFLAQVDISHMNB-AFARHQOCSA-N chembl399021 Chemical compound C1=2C(N)=NC=NC=2N([C@@H]2C[C@@H](CN3CCCC3)C2)C=C1C(C=1)=CC=CC=1OCC1=CC=CC=C1 LSFLAQVDISHMNB-AFARHQOCSA-N 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 150000004795 grignard reagents Chemical class 0.000 claims 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims 1
- 239000012280 lithium aluminium hydride Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- BUCAFRXFNHCHRU-UHFFFAOYSA-N n-[[3-[4-amino-5-(3-phenylmethoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]cyclobutyl]methyl]acetamide Chemical compound C1C(CNC(=O)C)CC1N1C2=NC=NC(N)=C2C(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=C1 BUCAFRXFNHCHRU-UHFFFAOYSA-N 0.000 claims 1
- 125000005936 piperidyl group Chemical group 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0111764A GB0111764D0 (en) | 2001-05-14 | 2001-05-14 | Organic compounds |
| GB0204752A GB0204752D0 (en) | 2002-02-28 | 2002-02-28 | Organic compounds |
| PCT/EP2002/005239 WO2002092599A1 (en) | 2001-05-14 | 2002-05-13 | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-d) pyrimidine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004533454A JP2004533454A (ja) | 2004-11-04 |
| JP2004533454A5 true JP2004533454A5 (https=) | 2005-07-07 |
| JP4099399B2 JP4099399B2 (ja) | 2008-06-11 |
Family
ID=26246078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002589483A Expired - Fee Related JP4099399B2 (ja) | 2001-05-14 | 2002-05-13 | ４−アミノ−５−フェニル−７−シクロブチル−ピロロ［２，３−ｄ］ピリミジン誘導体 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7326699B2 (https=) |
| EP (1) | EP1390369B1 (https=) |
| JP (1) | JP4099399B2 (https=) |
| KR (1) | KR100583704B1 (https=) |
| CN (1) | CN1264844C (https=) |
| AR (1) | AR035885A1 (https=) |
| AT (1) | ATE309245T1 (https=) |
| AU (1) | AU2002312905B2 (https=) |
| BR (1) | BR0209658A (https=) |
| CA (1) | CA2446435C (https=) |
| CO (1) | CO5540346A2 (https=) |
| CZ (1) | CZ20033067A3 (https=) |
| DE (1) | DE60207241T2 (https=) |
| ES (1) | ES2252465T3 (https=) |
| HU (1) | HUP0304082A3 (https=) |
| IL (1) | IL158697A0 (https=) |
| MX (1) | MXPA03010402A (https=) |
| MY (1) | MY124853A (https=) |
| NO (1) | NO20034929L (https=) |
| NZ (1) | NZ529256A (https=) |
| PE (1) | PE20021096A1 (https=) |
| PL (1) | PL363866A1 (https=) |
| RU (1) | RU2305682C2 (https=) |
| SK (1) | SK14022003A3 (https=) |
| TW (1) | TWI238824B (https=) |
| WO (1) | WO2002092599A1 (https=) |
Families Citing this family (152)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
| US7217796B2 (en) | 2002-05-24 | 2007-05-15 | Schering Corporation | Neutralizing human anti-IGFR antibody |
| GB0226370D0 (en) * | 2002-11-12 | 2002-12-18 | Novartis Ag | Organic compounds |
| GB0302748D0 (en) * | 2003-02-06 | 2003-03-12 | Novartis Ag | Organic compounds |
| AR046071A1 (es) * | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos |
| WO2005011598A2 (en) * | 2003-07-31 | 2005-02-10 | University Of South Florida | Leukemia treatment method and composition |
| BRPI0413439A (pt) * | 2003-08-08 | 2006-10-17 | Novartis Ag | combinações compreendendo estaurosporinas |
| KR100872204B1 (ko) * | 2003-10-15 | 2008-12-09 | 오에스아이 파마슈티컬스, 인코포레이티드 | 이미다조피라진 티로신 키나제 억제제 |
| JP2007510434A (ja) | 2003-11-12 | 2007-04-26 | シェーリング コーポレイション | 多重遺伝子発現のためのプラスミドシステム |
| PE20050928A1 (es) | 2003-11-21 | 2005-11-08 | Schering Corp | Combinaciones terapeuticas de anticuerpo anti-igfr1 |
| ATE514434T1 (de) | 2004-02-25 | 2011-07-15 | Dana Farber Cancer Inst Inc | Hemmer des insulinartigen wachstumsfaktor- rezeptors-1 zur hemmung von tumorzellwachstum |
| TWI378934B (en) | 2004-04-02 | 2012-12-11 | Osi Pharm Inc | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| RS52545B (sr) | 2004-04-07 | 2013-04-30 | Novartis Ag | Inhibitori protein apoptoze (iap) |
| TW200613306A (en) | 2004-07-20 | 2006-05-01 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
| BRPI0514094A (pt) | 2004-08-02 | 2008-05-27 | Osi Pharm Inc | composto, composição, e, método de tratamento de distúrbio hiperproliferativo |
| EP2283831A3 (en) | 2004-12-03 | 2013-10-23 | Merck Sharp & Dohme Corp. | Biomakers for pre-selection of patients for anti-IGF1R therapy |
| WO2006113483A2 (en) * | 2005-04-15 | 2006-10-26 | Schering Corporation | Methods and compositions for treating or preventing cancer |
| JP5033119B2 (ja) * | 2005-04-25 | 2012-09-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | キナーゼ阻害剤としての新規アザ複素環化合物 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US20060281768A1 (en) * | 2005-06-10 | 2006-12-14 | Gaul Michael D | Thienopyrimidine and thienopyridine kinase modulators |
| US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
| US7825244B2 (en) | 2005-06-10 | 2010-11-02 | Janssen Pharmaceutica Nv | Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis |
| US8071768B2 (en) | 2005-06-10 | 2011-12-06 | Janssen Pharmaceutica, N.V. | Alkylquinoline and alkylquinazoline kinase modulators |
| KR20080019249A (ko) | 2005-06-15 | 2008-03-03 | 쉐링 코포레이션 | 안정한 항체 제형 |
| US7566721B2 (en) * | 2005-08-08 | 2009-07-28 | Osi Pharmaceuticals, Inc. | Substituted thienol[2,3-d]pyrimidines as kinase inhibitors |
| AU2006292278B2 (en) | 2005-09-20 | 2012-03-08 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| GB0520164D0 (en) * | 2005-10-04 | 2005-11-09 | Novartis Ag | Organic compounds |
| KR101443651B1 (ko) | 2005-10-18 | 2014-09-23 | 얀센 파마슈티카 엔.브이. | Ｆｌｔ-3 키나제의 억제 방법 |
| CA2627839C (en) * | 2005-11-02 | 2014-08-19 | Bayer Healthcare Ag | Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
| AR057960A1 (es) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
| US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
| JP2009520028A (ja) * | 2005-12-19 | 2009-05-21 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | Ｉｇｆｒ抑制剤および抗癌剤の併用 |
| GB0605120D0 (en) | 2006-03-14 | 2006-04-26 | Novartis Ag | Organic Compounds |
| DE102006016426A1 (de) * | 2006-04-07 | 2007-10-11 | Merck Patent Gmbh | Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren |
| US20090203718A1 (en) * | 2006-04-13 | 2009-08-13 | Smithkline Beecham (Cork) Ltd. | Cancer treatment method |
| NZ572073A (en) | 2006-04-20 | 2011-09-30 | Janssen Pharmaceutica Nv | Heterocyclic compounds as inhibitors of c-fms kinase |
| BRPI0710548B8 (pt) | 2006-04-20 | 2021-05-25 | Janssen Pharmaceutica Nv | inibidores de c-fms cinase, composição farmacêutica e forma de dosagem farmacêutica |
| US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
| MX2008014292A (es) | 2006-05-09 | 2008-11-18 | Novartis Ag | Combinacion que comprende un quelante de hierro y un agente anti-neoplastico, y uso de la misma. |
| WO2008037477A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as p13k lipid kinase inhibitors |
| US20080119463A1 (en) * | 2006-11-16 | 2008-05-22 | Wyeth | 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML) |
| TW200838559A (en) * | 2006-11-29 | 2008-10-01 | Imclone Systems Inc | Insulin-like growth factor-1 receptor antagonists for modulation of weight and liposity |
| CA2672828A1 (en) * | 2006-12-13 | 2008-06-26 | Schering Corporation | Methods of treatment |
| WO2008076143A1 (en) * | 2006-12-18 | 2008-06-26 | Osi Pharmaceuticals, Inc. | Combination of igfr inhibitor and anti-cancer agent |
| BRPI0807812A2 (pt) | 2007-02-15 | 2020-06-23 | Novartis Ag | Combinações de lbh589 com outros agentes terapêuticos para tratar câncer |
| JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
| EP2247596A2 (en) | 2008-01-11 | 2010-11-10 | Natco Pharma Limited | Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents |
| JP2011510018A (ja) * | 2008-01-18 | 2011-03-31 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 癌治療のためのイミダゾピラジノール誘導体 |
| WO2009118292A1 (en) | 2008-03-24 | 2009-10-01 | Novartis Ag | Arylsulfonamide-based matrix metalloprotease inhibitors |
| NZ588069A (en) | 2008-03-26 | 2012-06-29 | Novartis Ag | Hydroxamate-based inhibitors of deacetylases b |
| EP2283020B8 (en) * | 2008-05-19 | 2012-12-12 | OSI Pharmaceuticals, LLC | Substituted imidazopyr-and imidazotri-azines |
| WO2010054264A1 (en) | 2008-11-07 | 2010-05-14 | Triact Therapeutics, Inc. | Use of catecholic butane derivatives in cancer therapy |
| WO2010083617A1 (en) | 2009-01-21 | 2010-07-29 | Oncalis Ag | Pyrazolopyrimidines as protein kinase inhibitors |
| PT2391366E (pt) | 2009-01-29 | 2013-02-05 | Novartis Ag | Benzimidazoles substituídos para o tratamento de astrocitomas |
| WO2010099139A2 (en) | 2009-02-25 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Combination anti-cancer therapy |
| US20110171124A1 (en) | 2009-02-26 | 2011-07-14 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the EMT status of tumor cells in vivo |
| JP2012519282A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
| EP2401614A1 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| EP2408479A1 (en) | 2009-03-18 | 2012-01-25 | OSI Pharmaceuticals, LLC | Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor |
| WO2010123792A1 (en) | 2009-04-20 | 2010-10-28 | Osi Pharmaceuticals, Inc. | Preparation of c-pyrazine-methylamines |
| EP2427192A1 (en) * | 2009-05-07 | 2012-03-14 | OSI Pharmaceuticals, LLC | Use of osi-906 for treating adrenocortical carcinoma |
| UY32730A (es) | 2009-06-26 | 2011-01-31 | Novartis Ag | Inhibidores de cyp17 |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| JP5781510B2 (ja) | 2009-08-12 | 2015-09-24 | ノバルティス アーゲー | ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用 |
| PE20121148A1 (es) | 2009-08-17 | 2012-09-07 | Intellikine Llc | Compuestos heterociclicos y usos de los mismos |
| JP5775871B2 (ja) | 2009-08-20 | 2015-09-09 | ノバルティス アーゲー | ヘテロ環式オキシム化合物 |
| WO2011023677A1 (en) | 2009-08-26 | 2011-03-03 | Novartis Ag | Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators |
| WO2011029915A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Ether derivatives of bicyclic heteroaryls |
| JP5466767B2 (ja) | 2009-11-04 | 2014-04-09 | ノバルティス アーゲー | Ｍｅｋ阻害剤として有用なヘテロ環式スルホンアミド誘導体 |
| WO2011064211A1 (en) * | 2009-11-25 | 2011-06-03 | Novartis Ag | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls |
| CA2781218A1 (en) | 2009-12-08 | 2011-06-16 | Novartis Ag | Heterocyclic sulfonamide derivatives |
| CU24130B1 (es) | 2009-12-22 | 2015-09-29 | Novartis Ag | Isoquinolinonas y quinazolinonas sustituidas |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| US9109227B2 (en) | 2010-01-05 | 2015-08-18 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | FLT3 receptor antagonists for the treatment or the prevention of pain disorders |
| WO2011083391A2 (en) | 2010-01-05 | 2011-07-14 | Pfizer Inc. | Biomarkers for anti-igf-ir cancer therapy |
| MX2012008083A (es) | 2010-01-12 | 2012-08-15 | Ab Science | Inhibidores de triazol y oxazol quinaza. |
| CA2783665A1 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| CA2783656A1 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| EP2544672A1 (en) | 2010-03-09 | 2013-01-16 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| US8946260B2 (en) | 2010-09-16 | 2015-02-03 | Novartis Ag | 17α-hydroxylase/C17,20-lyase inhibitors |
| AU2011346567A1 (en) | 2010-12-21 | 2013-07-25 | Novartis Ag | Bi-heteroaryl compounds as Vps34 inhibitors |
| WO2012107500A1 (en) | 2011-02-10 | 2012-08-16 | Novartis Ag | [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
| US20120214830A1 (en) | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
| WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
| JP2014507465A (ja) * | 2011-03-08 | 2014-03-27 | ノバルティス アーゲー | フルオロフェニル二環式ヘテロアリール化合物 |
| WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
| EP2702173A1 (en) | 2011-04-25 | 2014-03-05 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
| AU2012249421B9 (en) | 2011-04-28 | 2015-10-22 | Novartis Ag | 17alpha-hydroxylase/C17,20-lyase inhibitors |
| BR112013028430A2 (pt) * | 2011-05-04 | 2017-08-01 | Merck Sharp & Dohme | composto, composição farmacêutica, método para tratar uma doença ou condição mediada por tirosina quinase do baço (syk), e, uso de uma quantidade terapeuticamente eficiente do composto |
| BR112013031201A2 (pt) | 2011-06-09 | 2017-01-31 | Novartis Ag | derivados de sulfonamida heterocíclicos, composição farmacêutica os compreendendo, uso, processo para a fabricação de (r)-n-(4,5-difluoro-6-((2-fluoro-4-iodofenil)amino)benzofuran-7-il)-1-(2,3-di-idroxipropil)ciclopropano-5 1-sulfonamida e kit |
| WO2012175520A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
| EP2721007B1 (en) | 2011-06-20 | 2015-04-29 | Novartis AG | Cyclohexyl isoquinolinone compounds |
| JP2014518256A (ja) | 2011-06-27 | 2014-07-28 | ノバルティス アーゲー | テトラヒドロ−ピリド−ピリミジン誘導体の固体形態および塩類 |
| US12194002B2 (en) | 2011-08-17 | 2025-01-14 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol |
| EA026655B1 (ru) | 2011-09-15 | 2017-05-31 | Новартис Аг | 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ |
| BR112014007788A2 (pt) * | 2011-10-03 | 2017-04-18 | Univ North Carolina Chapel Hill | compostos de pirrolopirimidina para tratamento do câncer |
| JP5992054B2 (ja) | 2011-11-29 | 2016-09-14 | ノバルティス アーゲー | ピラゾロピロリジン化合物 |
| JP5903499B2 (ja) | 2011-12-22 | 2016-04-13 | ノバルティス アーゲー | ジヒドロ−ベンゾ−オキサジンおよびジヒドロ−ピリド−オキサジン誘導体 |
| WO2013093850A1 (en) | 2011-12-22 | 2013-06-27 | Novartis Ag | Quinoline derivatives |
| BR112014015442A8 (pt) | 2011-12-23 | 2017-07-04 | Novartis Ag | compostos e composições para inibir a interação de bcl2 com parceiros de ligação |
| JP2015503518A (ja) | 2011-12-23 | 2015-02-02 | ノバルティス アーゲー | Ｂｃｌ２と結合相手の相互作用を阻害するための化合物 |
| EP2794588A1 (en) | 2011-12-23 | 2014-10-29 | Novartis AG | Compounds for inhibiting the interaction of bcl2 with binding partners |
| EP2794592A1 (en) | 2011-12-23 | 2014-10-29 | Novartis AG | Compounds for inhibiting the interaction of bcl2 with binding partners |
| US8815926B2 (en) | 2012-01-26 | 2014-08-26 | Novartis Ag | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases |
| JP2015512425A (ja) | 2012-04-03 | 2015-04-27 | ノバルティス アーゲー | チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用 |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| EP2855483B1 (en) | 2012-05-24 | 2017-10-25 | Novartis AG | Pyrrolopyrrolidinone compounds |
| JP6427097B2 (ja) | 2012-06-15 | 2018-11-21 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | 癌を処置するための組成物および該組成物を製造するための方法 |
| JP6290884B2 (ja) | 2012-08-07 | 2018-03-07 | ヤンセン ファーマシューティカ エヌ．ベー． | ｃ−ＦＭＳキナーゼ阻害剤の調製プロセス |
| IN2015DN00659A (https=) | 2012-08-07 | 2015-06-26 | Janssen Pharmaceutica Nv | |
| JP6407504B2 (ja) | 2012-09-21 | 2018-10-17 | アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 恒常的に活性であるリン酸化型ｆｌｔ３キナーゼの阻害方法 |
| TW201422625A (zh) | 2012-11-26 | 2014-06-16 | Novartis Ag | 二氫－吡啶并－□衍生物之固體形式 |
| BR112015016282A2 (en) | 2013-01-07 | 2017-07-11 | Arog Pharmaceuticals, Inc. | crenolanib for treatment of mutated flt3 proliferative disorders |
| WO2014115080A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
| US9403827B2 (en) | 2013-01-22 | 2016-08-02 | Novartis Ag | Substituted purinone compounds |
| WO2014128612A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Quinazolin-4-one derivatives |
| JP6255038B2 (ja) | 2013-02-26 | 2017-12-27 | トリアクト セラピューティクス，インク． | 癌治療 |
| EP2968340A4 (en) | 2013-03-15 | 2016-08-10 | Intellikine Llc | COMBINING KINASE INHIBITORS AND USES THEREOF |
| WO2014155268A2 (en) | 2013-03-25 | 2014-10-02 | Novartis Ag | Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity |
| EP2983674A4 (en) | 2013-04-08 | 2017-05-10 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
| US20150018376A1 (en) | 2013-05-17 | 2015-01-15 | Novartis Ag | Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof |
| UY35675A (es) | 2013-07-24 | 2015-02-27 | Novartis Ag | Derivados sustituidos de quinazolin-4-ona |
| WO2015022664A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
| WO2015022663A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
| US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
| US9381246B2 (en) | 2013-09-09 | 2016-07-05 | Triact Therapeutics, Inc. | Cancer therapy |
| US9657007B2 (en) | 2013-09-22 | 2017-05-23 | Calitor Sciences, Llc | Substituted aminopyrimidine compounds and methods of use |
| US10463658B2 (en) | 2013-10-25 | 2019-11-05 | Videra Pharmaceuticals, Llc | Method of inhibiting FLT3 kinase |
| WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
| MX2016012574A (es) | 2014-03-28 | 2017-09-26 | Calitor Sciences Llc | Compuestos heteroarilo sustituidos y metodos de uso. |
| KR20160132496A (ko) | 2014-04-03 | 2016-11-18 | 인빅터스 온콜로지 피비티. 엘티디. | 초분자 조합 치료제 |
| WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
| ES2831416T3 (es) | 2014-07-31 | 2021-06-08 | Novartis Ag | Terapia de combinación de un inhibidor de MET y un inhibidor de EGFR |
| CN107001283B (zh) | 2014-07-31 | 2021-05-25 | 国家健康与医学研究院 | Flt3受体拮抗剂 |
| WO2017044434A1 (en) | 2015-09-11 | 2017-03-16 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
| EP3254698A1 (en) | 2016-06-08 | 2017-12-13 | Universite De Montpellier | Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain |
| BR112019008762A2 (pt) | 2016-11-02 | 2019-07-16 | Arog Pharmaceuticals, Inc. | método para o tratamento de um distúrbio proliferativo mutado em flt3 |
| US12534764B2 (en) | 2016-11-02 | 2026-01-27 | Arog Pharmaceuticals, Inc. | Crenolanib for treating FLT3 mutated proliferative disorders associated mutations |
| WO2018211018A1 (en) | 2017-05-17 | 2018-11-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Flt3 inhibitors for improving pain treatments by opioids |
| WO2019057649A1 (en) | 2017-09-19 | 2019-03-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA |
| US10683297B2 (en) | 2017-11-19 | 2020-06-16 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| JP7021356B2 (ja) | 2017-12-21 | 2022-02-16 | ヘフェイ インスティテューツ オブ フィジカル サイエンス， チャイニーズ アカデミー オブ サイエンシーズ | ピリミジン誘導体系キナーゼ阻害剤類 |
| AU2019209960B2 (en) | 2018-01-20 | 2023-11-23 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| BR112022003663A2 (pt) | 2019-08-28 | 2022-05-24 | Horizon Therapeutics Ireland Dac | Método para tratar oftalmopatia tireoidiana (ted) em um indivíduo com ted; método para reduzir proptose em pelo menos 2 mm em um indivíduo com oftalmopatia tireoidiana (ted); método para tratar ou reduzir a gravidade de diplopia em um indivíduo com oftalmopatia tireoidiana (ted); método para tratar ou reduzir a gravidade de oftalmopatia tireoidiana (ted); método para reduzir proptose em um olho em um indivíduo com oftalmopatia tireoidiana (ted); método para reduzir pontuação de atividade clínica (cas) de oftalmopatia tireoidiana (ted); método para a) reduzir proptose em pelo menos 2 mm e b) reduzir a pontuação de atividade clínica (cas) em um indivíduo com oftalmopatia tireoidiana (ted); e método para melhorar a qualidade de vida em um indivíduo com oftalmopatia tireoidiana (ted) |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN115916966A (zh) * | 2020-01-30 | 2023-04-04 | 加利福尼亚大学董事会 | Strad结合剂及其用途 |
| WO2022019998A1 (en) | 2020-07-20 | 2022-01-27 | Arog Pharmaceuticals, Inc. | Crystal forms of crenolanib and methods of use thereof |
| WO2025014774A1 (en) | 2023-07-07 | 2025-01-16 | Viridian Therapeutics, Inc. | Methods of treating active and chronic thyroid eye disease |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE247469T1 (de) * | 1995-06-07 | 2003-09-15 | Pfizer | Heterocyclische kondensierte pyrimidin-derivate |
| CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
| AU3176297A (en) | 1996-06-25 | 1998-01-14 | Novartis Ag | Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof |
| US6413971B1 (en) | 1996-11-27 | 2002-07-02 | Pfizer Inc | Fused bicyclic pyrimidine derivatives |
| DK0970084T3 (da) * | 1997-03-19 | 2003-09-29 | Abbott Gmbh & Co Kg | Pyrrolo[2,3-d]pyrimidiner og deres anvendelse som inhibitorer for tyrosinkinase |
| YU76100A (sh) | 1998-06-02 | 2003-12-31 | Osi Pharmaceuticals Inc. | Pirolo(2,3-d) pirimidin preparati i njihova primena |
| JP2002522506A (ja) | 1998-08-13 | 2002-07-23 | トーマス・ジェファーソン・ユニバーシティ | インスリン様増殖因子−ｉ受容体に向けられるオリゴヌクレオチドを用いた腫瘍の処置 |
| CA2344249A1 (en) | 1998-09-18 | 2000-03-30 | Basf Aktiengesellschaft | Pyrrolopyrimidines as protein kinase inhibitors |
| US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| CA2344262A1 (en) | 1998-09-18 | 2000-03-30 | Basf Aktiengesellschaft | 4-aminopyrrolopyrimidines as kinase inhibitors |
| WO2001072751A1 (en) | 2000-03-29 | 2001-10-04 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
| AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
| US20050215564A1 (en) * | 2002-02-14 | 2005-09-29 | Stiles Charles D | Methods and compositions for treating hyperproliferative conditions |
| ES2283744T3 (es) | 2002-02-14 | 2007-11-01 | Dana-Farber Cancer Institute, Inc. | Metodos y composiciones para el tratamiento de condiciones hiperproliferativas. |
-
2002
- 2002-05-10 AR ARP020101716A patent/AR035885A1/es not_active Application Discontinuation
- 2002-05-10 TW TW091109801A patent/TWI238824B/zh active
- 2002-05-13 MY MYPI20021716A patent/MY124853A/en unknown
- 2002-05-13 DE DE60207241T patent/DE60207241T2/de not_active Expired - Lifetime
- 2002-05-13 CA CA002446435A patent/CA2446435C/en not_active Expired - Fee Related
- 2002-05-13 EP EP02738065A patent/EP1390369B1/en not_active Expired - Lifetime
- 2002-05-13 NZ NZ529256A patent/NZ529256A/en unknown
- 2002-05-13 RU RU2003134149/04A patent/RU2305682C2/ru not_active IP Right Cessation
- 2002-05-13 CZ CZ20033067A patent/CZ20033067A3/cs unknown
- 2002-05-13 ES ES02738065T patent/ES2252465T3/es not_active Expired - Lifetime
- 2002-05-13 HU HU0304082A patent/HUP0304082A3/hu unknown
- 2002-05-13 PL PL02363866A patent/PL363866A1/xx unknown
- 2002-05-13 US US10/477,594 patent/US7326699B2/en not_active Expired - Fee Related
- 2002-05-13 MX MXPA03010402A patent/MXPA03010402A/es active IP Right Grant
- 2002-05-13 AU AU2002312905A patent/AU2002312905B2/en not_active Ceased
- 2002-05-13 AT AT02738065T patent/ATE309245T1/de active
- 2002-05-13 CN CNB028100034A patent/CN1264844C/zh not_active Expired - Fee Related
- 2002-05-13 SK SK1402-2003A patent/SK14022003A3/sk unknown
- 2002-05-13 JP JP2002589483A patent/JP4099399B2/ja not_active Expired - Fee Related
- 2002-05-13 IL IL15869702A patent/IL158697A0/xx unknown
- 2002-05-13 BR BR0209658-7A patent/BR0209658A/pt not_active IP Right Cessation
- 2002-05-13 WO PCT/EP2002/005239 patent/WO2002092599A1/en not_active Ceased
- 2002-05-13 KR KR1020037014725A patent/KR100583704B1/ko not_active Expired - Fee Related
- 2002-05-14 PE PE2002000402A patent/PE20021096A1/es not_active Application Discontinuation
-
2003
- 2003-11-05 NO NO20034929A patent/NO20034929L/no not_active Application Discontinuation
- 2003-12-01 CO CO03105541A patent/CO5540346A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004533454A5 (https=) | ||
| RU2003134149A (ru) | Производные 4-амино-5-фенил-7- циклобутилпирроло[2,3-d]пиримидина | |
| CA2453881A1 (en) | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | |
| JP2005502683A5 (https=) | ||
| EP2389382B1 (en) | Amino-heterocyclic compounds used as pde9 inhibitors | |
| JP2005501077A5 (https=) | ||
| JP5647998B2 (ja) | 免疫抑制剤としてのチアゾロピリミジン調節因子 | |
| US20110165183A1 (en) | Piperidine derivatives as jak3 inhibitors | |
| WO2019165073A1 (en) | Shp2 phosphatase inhibitors and methods of use thereof | |
| RU2012111215A (ru) | Гетероциклические соединения в качестве ингибиторов янускиназы | |
| RU2005117340A (ru) | Производные пиримидо {4,5-d}пиримидина, обладающие противораковой активностью | |
| JP2014503566A5 (https=) | ||
| EP1476192B1 (en) | Methods and compositions for treating hyperproliferative conditions | |
| JP2021523177A5 (https=) | ||
| CA2527496A1 (en) | 4-substituted derivatives of pyrazolo [3,4-d] pyrimidine and pyrrolo [2,3-d] pyrimidine and uses thereof | |
| KR20220059519A (ko) | 키나제 억제제에 의한 한선염의 치료 | |
| US20130184273A1 (en) | Bicyclic pyrimidines | |
| US20050215564A1 (en) | Methods and compositions for treating hyperproliferative conditions | |
| RU2007147595A (ru) | Производные индактерола и фосфодиэстеразные ингибиторы для лечения заболеваний дыхательных путей | |
| JP2004529119A5 (https=) | ||
| JPWO2019164949A5 (https=) | ||
| JP2013512215A5 (https=) | ||
| ZA200308378B (en) | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-D) pyrimidine derivatives. | |
| CA2523763A1 (en) | Fused pyrimidine derivative | |
| US20070219220A1 (en) | Pyrazolopyrimidinethione Derivatives, Salts and Solvates Thereof, Preparation Methods and Use Thereof |